TG Therapeutics Inc (TGTX)
Return on assets (ROA)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 23,383 | 12,672 | -198,335 | -348,101 | -279,381 |
| Total assets | US$ in thousands | 577,690 | 329,587 | 193,572 | 379,629 | 625,642 |
| ROA | 4.05% | 3.84% | -102.46% | -91.70% | -44.66% |
December 31, 2024 calculation
ROA = Net income ÷ Total assets
= $23,383K ÷ $577,690K
= 4.05%
TG Therapeutics Inc's return on assets (ROA) has shown a volatile trend over the years. In December 2020, the ROA was significantly negative at -44.66%, indicating that the company's assets were not generating sufficient profits. This trend worsened in December 2021 and 2022, with ROA plummeting to -91.70% and -102.46% respectively, reflecting deteriorating financial performance and efficiency in utilizing assets.
However, there was a notable turnaround in December 2023, where the ROA improved to a positive 3.84%. This suggests that TG Therapeutics Inc effectively utilized its assets to generate a modest return. The positive momentum continued into December 2024, with the ROA further increasing to 4.05%, indicating improved asset efficiency and profitability.
Overall, while the company faced significant challenges in the past, the recent positive trend in ROA indicates a potential turnaround in its financial performance and asset management strategies. Continued monitoring of the ROA will be essential to assess the company's ability to maintain and further improve its profitability and efficiency going forward.
Peer comparison
Dec 31, 2024